"We are currently completing the analysis of the ACCLAIM data in preparation for releasing full study results at this venue and at the World Congress of Cardiology in Barcelona, Spain, both in September. Based on our ongoing review of the data, we also look forward to providing an update on our plans to advance the commercial development of Celacade during our second quarter conference call in mid-July."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.